Publications

Journal Articles

  1. & Genetic and Epigenetic Intra-tumour Heterogeneity in Colorectal Cancer. World Journal of Surgery 41(5), 1375-1383.
  2. & Extramural vascular invasion and response to neoadjuvant chemoradiotherapy in rectal cancer: Influence of the CpG island methylator phenotype. World Journal of Gastrointestinal Oncology 9(5), 209
  3. & Development of an in vitro PIG-A gene mutation assay in human cells. Mutagenesis 32(2), 283-297.
  4. & Extensive telomere erosion is consistent with localised clonal expansions in Barrett’s metaplasia. PLOS ONE 12(3), e0174833
  5. & Critical review of the current and future challenges associated with advancedin vitrosystems towards the study of nanoparticle (secondary) genotoxicity. Mutagenesis 32(1), 233-241.
  6. & Is Nickel Chloride really a Non-Genotoxic Carcinogen?. Basic & Clinical Pharmacology & Toxicology
  7. & A comparison of the genotoxicity of benzo[a]pyrene in four cell lines with differing metabolic capacity. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 808, 8-19.
  8. & Genetic toxicity assessment of engineered nanoparticles using a 3D in vitro skin model (EpiDerm™). Particle and Fibre Toxicology 13(1)
  9. & Genotoxic capacity of Cd/Se semiconductor quantum dots with differing surface chemistries. Mutagenesis, gev061
  10. & The clastogenicity of 4NQO is cell-type dependent and linked to cytotoxicity, length of exposure and p53 proficiency. Mutagenesis, gev069
  11. & Review of the development of DNA methylation as a marker of response to neoadjuvant therapy and outcomes in rectal cancer. Clinical Epigenetics 7(1)
  12. & Cell Type-Dependent Changes in CdSe/ZnS Quantum Dot Uptake and Toxic Endpoints. Toxicological Sciences 144(2), 246-258.
  13. & A Newly Developed Nested PCR Assay for the Detection of Helicobacter pylori in the Oral Cavity. Journal of Clinical Gastroenterology, 1
  14. & Acute Dosing and p53-Deficiency Promote Cellular Sensitivity to DNA Methylating Agents. Toxicological Sciences 144, 357-365.
  15. & Reflux composition influences the level of NF-κB activation and upstream kinase preference in oesophageal adenocarcinoma cells. International Journal of Cancer 136, 527-535.
  16. Chromosome Breakage Induced by the Genotoxic Agents Mitomycin C and Cytosine arabinoside. Toxicological Sciences 140(1), 94-102.
  17. Automation and validation of micronucleus detection in the 3D EpiDerm human reconstructed skin. Mutagenesis 29(3), 165-175.
  18. Genotoxins induce binucleation in L5178Y and TK6 cells. Mutation Research Genetic Toxicology 770, 29-34.
  19. Recommendations, evaluation and validation of a semi-automated, fluorescent-based scoring protocol. Mutagenesis 29(3), 155-164.
  20. Zaïr, Z.M., Johnson, G.E., Griffiths, A.P., Jenkins, G.J. Diagnostic correlation between the expression of the DNA repair enzymeN-methylpurine DNA glycosylase and esophageal adenocarcinoma onset: a retrospective pilot study. Diseases of the Esophagus 26(6), 644-650.
  21. Thomas, A.D., Jenkins, G.J.S., Kaina, B., Bodger, O.G., Tomaszowski, K.H., Lewis, P.D., Doak, S.H., Johnson, G.E. Influence of DNA Repair on Nonlinear Dose-Responses for Mutation. Toxicological Sciences 132(1), 87-95.
  22. Manshian, B.B., Jenkins, G.J.S., Williams, P.M., Wright, C., Barron, A.R., Brown, A.P., Hondow, N., Dunstan, P.R., Rickman, R., Brady, K., Doak, S.H. Single-walled carbon nanotubes: differential genotoxic potential associated with physico-chemical properties. Nanotoxicology 7(2), 144-156.
  23. Haboubi, H.N., Doak, S.H., Jenkins, G.J. The jury is still out on the safety of silver nanoparticles. BMJ 345(jan15 4), f227-f227.
  24. Rawat, N., Alhamdani, A., McAdam, E., Cronin, J., Eltahir, Z., Lewis, P., Griffiths, P., Baxter, J.N., Jenkins, G.J.S. Curcumin abrogates bile-induced NF-κB activity and DNA damage in vitro and suppresses NF-κB activity whilst promoting apoptosis in vivo, suggesting chemopreventative potential in Barrett’s oesophagus. Clinical and Translational Oncology 14(4), 302-311.
  25. Doak, S.H., Manshian, B., Jenkins, G.J.S., Singh, N. In vitro genotoxicity testing strategy for nanomaterials and the adaptation of current OECD guidelines. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 745(1-2), 104-111.
  26. Johnson, G.E., Zaïr, Z.M., Bodger, O.G., Lewis, P.D., Rees, B.J., Verma, J.R., Thomas, A.D., Doak, S.H., Jenkins, G.J.S. Investigating Mechanisms for Non-linear Genotoxic Responses, and Analysing Their Effects in Binary Combination. Genes and Environment 34(4), 179-185.
  27. Singh, N., Jenkins, G.J.S., Nelson, B.C., Marquis, B.J., Maffeis, T.G.G., Brown, A.P., Williams, P.M., Wright, C.J., Doak, S.H. The role of iron redox state in the genotoxicity of ultrafine superparamagnetic iron oxide nanoparticles. Biomaterials 33(1), 163-170.
  28. & Inducible Nitric Oxide Synthase (iNOS) and Nitric Oxide (NO) are Important Mediators of Reflux-induced Cell Signalling in Esophageal Cells. Carcinogenesis 33, 2035
  29. & Pro-oxidant Induced DNA Damage in Human Lymphoblastoid Cells: Homeostatic Mechanisms of Genotoxic Tolerance. Toxicological Sciences 128, 387
  30. Griffiths, S.M., Singh, N., Jenkins, G.J.S., Williams, P.M., Orbaek, A.W., Barron, A.R., Wright, C.J., Doak, S.H. Dextran Coated Ultrafine Superparamagnetic Iron Oxide Nanoparticles: Compatibility with Common Fluorometric and Colorimetric Dyes. Analytical Chemistry 83(10), 3778-3785.
  31. Cronin, J., Alhamdani, A., Griffiths, A.P., Baxter, J.N., Brown, T., Jenkins, G.J.S. In vitro and ex vivo models of extended reflux exposure demonstrate that weakly acidic mixed reflux heightens NF-kB-mediated gene expression. Diseases of the Esophagus 24(5), 360-370.
  32. Hughes, R., Parry, J., Beynon, J., Jenkins, G. Molecular changes consistent with increased proliferation and invasion are common in rectal cancer. Clinical and Translational Oncology 13(10), 753-759.
  33. & Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in High-Grade Dysplasia and Adenocarcinoma of the Esophagus and May Represent a Biomarker of Histological Progression in Barrett's Esophagus (BE). The American Journal of Gastroenterology 106(1), 46-56.
  34. & N-Methylpurine DNA Glycosylase Plays a Pivotal Role in the Threshold Response of Ethyl Methanesulfonate-Induced Chromosome Damage. Toxicological Sciences 119(2), 346-358.
  35. Jenkins, G.J.S., Zaïr, Z., Johnson, G.E., Doak, S.H. Genotoxic thresholds, DNA repair, and susceptibility in human populations. Toxicology 278(3), 305-310.
  36. Cronin, J., Williams, L., McAdam, E., Eltahir, Z., Griffiths, P., Baxter, J., Jenkins, G. The role of secondary bile acids in neoplastic development in the oesophagus. Biochemical Society Transactions 38(2), 337-342.
  37. Johnson, G.E., Jenkins, G.J., Thomas, A.D., Doak, S.H. Vinblastine and diethylstilboestrol tested in the in vitro mammalian cell micronucleus test (MNvit) at Swansea University UK in support of OECD draft Test Guideline 487. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 702(2), 189-192.
  38. & Aneuploidy involving chromosome 1 may be an early predictive marker of intestinal type gastric cancer. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 669(1-2), 104-111.
  39. & Non-linear dose–response of DNA-reactive genotoxins: Recommendations for data analysis. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 678(2), 95-100.
  40. & Confounding experimental considerations in nanogenotoxicology. Mutagenesis 24(4), 285-293.
  41. Singh, N., Manshian, B., Jenkins, G.J.S., Griffiths, S.M., Williams, P.M., Maffeis, T.G.G., Wright, C.J., Doak, S.H. NanoGenotoxicology: The DNA damaging potential of engineered nanomaterials. Biomaterials 30(23-24), 3891-3914.
  42. & Confounding experimental considerations in nano(geno)toxicology.. Mutagenesis 24, 285-293.
  43. & Non-linear dose¨Cresponse of DNA-reactive genotoxins: Recommendations for data analysis.. Mutat. Res. (Gen. Tox) 678, 95-100.
  44. & No-observed effect levels are associated with up-regulation of MGMT following MMS exposure. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 648(1-2), 9-14.
  45. & The bile acid deoxycholic acid has a non-linear dose response for DNA damage and possibly NF- B activation in oesophageal cells, with a mechanism of action involving ROS. Mutagenesis 23(5), 399-405.
  46. Rai, N., Jenkins, G.J.S., McAdam, E., Hibbitts, S.J., Fiander, A.N., Powell, N.G. Human papillomavirus infection in Barrett's oesophagus in the UK: An infrequent event. Journal of Clinical Virology 43(2), 250-252.
  47. Beasley, W.D., Beynon, J., Jenkins, G.J.S., Parry, J.M. Reprimo 824 G>C and p53R2 4696 C>G single nucleotide polymorphisms and colorectal cancer: a case–control disease association study. International Journal of Colorectal Disease 23(4), 375-381.
  48. & No-observed effect levels are associated with up-regulation of MGMT following MMS exposure. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 648(1-2), 9-14.
  49. & The bile acid deoxycholic acid has a non-linear dose response for DNA damage and possibly NF-kB activation in oesophageal cells, with a mechanism of action involving ROS.. 23, 399-405.
  50. Ivil, K.D., Jenkins, S.A., Doak, S.H., Hawizy, A.M., Kynaston, H.G., Parry, E.M., Jenkins, G.J.S., Parry, J.M., Stephenson, T.P. Identification of Early p53 Mutations in Clam Ileocystoplasties Using Restriction Site Mutation Assay. Urology 70(5), 905-909.
  51. Jenkins, G.J.S., Mikhail, J., Alhamdani, A., Brown, T.H., Caplin, S., Manson, J.M., Bowden, R., Toffazal, N., Griffiths, A.P., Parry, J.M., Baxter, J.N. Immunohistochemical study of nuclear factor- B activity and interleukin-8 abundance in oesophageal adenocarcinoma; a useful strategy for monitoring these biomarkers. Journal of Clinical Pathology 60(11), 1232-1237.
  52. Doak, S.H., Jenkins, G.J.S., Johnson, G.E., Quick, E., Parry, E.M., Parry, J.M. Mechanistic Influences for Mutation Induction Curves after Exposure to DNA-Reactive Carcinogens. Cancer Research 67(8), 3904-3911.
  53. & Deoxycholic acid at neutral and acid pH, is genotoxic to oesophageal cells through the induction of ROS: the potential role of anti-oxidants in Barrett's oesophagus. Carcinogenesis 28
  54. Jenkins, G.J.S., Doak, S.H., Johnson, G.E., Quick, E., Waters, E.M., Parry, J.M. Do dose response thresholds exist for genotoxic alkylating agents?. Mutagenesis 20(6), 389-398.
  55. & Fluorescence in situ hybridisation analysis of chromosomal aberrations in gastric tissue: the potential involvement of Helicobacter pylori. British Journal of Cancer 92(9), 1759-1766.
  56. Doak, S.H., Jenkins, G.J.S., Parry, E.M., Griffiths, A.P., Baxter, J.N., Parry, J.M. Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus—their association with aneuploidy and neoplastic progression. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 547(1-2), 133-144.
  57. Doak, S.H., Saidely, D., Jenkins, G.J.S., Parry, E.M., Griffiths, A.P., Baxter, J.N., Parry, J.M. Generation of locus-specific probes for interphase fluorescence in situ hybridisation—application in Barrett's esophagus. Experimental and Molecular Pathology 77(1), 26-33.
  58. Jenkins, G.J.S. REVIEW The restriction site mutation (RSM) method: clinical applications. Mutagenesis 19(1), 3-11.
  59. Doak, S.H., Jenkins, G.J.S., Parry, E.M., Griffiths, A.P., Shah, V., Baxter, J.N., Parry, J.M. Characterisation of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinoma. British Journal of Cancer 89(9), 1729-1735.
  60. Morgan, C., Jenkins, G.J.S., Ashton, T., Griffiths, A.P., Baxter, J.N., Parry, E.M., Parry, J.M. Detection of p53 mutations in precancerous gastric tissue. British Journal of Cancer 89(7), 1314-1319.
  61. Jenkins, G.J.S., Doak, S.H., Griffiths, A.P., Tofazzal, N., Shah, V., Baxter, J.N., Parry, J.M. Early p53 mutations in nondysplastic Barrett's tissue detected by the restriction site mutation (RSM) methodology. British Journal of Cancer 88(8), 1271-1276.
  62. The bile acid deoxycholic acid (DCA) at neutral pH activates NF- B and induces IL-8 expression in oesophageal cells in vitro. Carcinogenesis 25(3), 317-323.
  63. Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus. Gut 52(5), 623-628.
  64. Croft, J., Parry, E.M., Jenkins, G.J.S., Doak, S.H., Baxter, J.N., Griffiths, A.P., Brown, T.H., Parry, J.M. Analysis of the premalignant stages of Barrett's oesophagus through to adenocarcinoma by comparative genomic hybridization. European Journal of Gastroenterology & Hepatology 14(11), 1179-1186.
  65. Jenkins, G.J.S., Doak, S.H., Parry, J.M., D'Souza, F.R., Griffiths, A.P., Baxter, J.N. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. British Journal of Surgery 89(7), 824-837.
  66. Jenkins, G.J.S., Stephens, L.A., Masnavi, N., Parry, J.M. Molecular analysis of the chemoprotective effects of topical sunscreen and vitamin C in preventing UV-induced and reactive oxygen species-induced DNA damage, respectively, using the PCR inhibition methodology. 22
  67. Jenkins, G.J.S., Williams, G.L., Beynon, J., Ye, Z., Baxter, J.N., Parry, J.M. Restriction enzymes in the analysis of genetic alterations responsible for cancer progression. British Journal of Surgery 89(1), 8-20.
  68. Song, H.-L., Jenkins, G.J.S., Ashby, J., Tinwell, H., Parry, J.M. The application of the restriction site mutation assay to compare 1-ethyl-1-nitrosourea-induced mutations between the endogenous p53 gene and the transgenic LacZ gene in MutaMouse testes. 16
  69. Jenkins, G.J.S., Morgan, C., Baxter, J.N., Parry, E.M., Parry, J.M. The detection of mutations induced in vitro in the human p53 gene by hydrogen peroxide with the restriction site mutation (RSM) assay. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 498(1-2), 135-144.
  70. Sueiro, R.A., Jenkins, G.J.S., Lyons, B.P., Harvey, J.S., Parry, J.M. Genotypic mutation analysis in the p53 gene of benzo[a]pyrene-treated European flounder (Platichthys flesus). Mutation Research/Genetic Toxicology and Environmental Mutagenesis 468(1), 63-71.
  71. Parry, J.M., Jenkins, G.J.S., Haddad, F., Bourner, R., Parry, E.M. In vitro and in vivo extrapolations of genotoxin exposures: consideration of factors which influence dose–response thresholds. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 464(1), 53-63.
  72. Jenkins, G.J.S., Parry, J.M. PCR-based methodology for the determination of the photoprotection afforded by sunscreen application. 29
  73. Jenkins, G.J.S., Parry, J.M. Restriction site mutation (RSM) analysis of 2-acetylaminofluorene (2-AAF)-induced mouse liver mutations and comparison with the measurement of in vivo micronucleus induction in the bone marrows of (2-AAF)-treated mice. Teratogenesis, Carcinogenesis, and Mutagenesis 20(3), 107-117.
  74. Jenkins, G.J.S., Burlinson, B., Parry, J.M. The polymerase inhibition assay: A methodology for the identification of DNA-damaging agents. Molecular Carcinogenesis 27(4), 289-297.
  75. Jenkins, G.J.S., Takahashi, N., Parry, J.M. A study of ENU-induced mutagenesis in the mouse using the restriction site mutation (RSM) assay. Teratogenesis, Carcinogenesis, and Mutagenesis 19(4), 281-292.
  76. Jenkins, G.J.S., Takahashi, N., Parry, J.M. Inverse restriction site mutation (iRSM) analysis. Mutation detection involving the formation of restriction enzyme sites in target genes. Mutagenesis 14(1), 37-42.
  77. Jenkins, G.J.S., Suzen, H.S., Sueiro, R.A., Parry, J.M. The restriction site mutation assay: a review of the methodology development and the current status of the technique. Mutagenesis 14(5), 439-448.
  78. Suzen, S., Jenkins, G.J.S., Parry, J.M. Application of the restriction site mutation technique toN-methyl-N-nitrosourea-induced mutations in the rat. Teratogenesis, Carcinogenesis, and Mutagenesis 18(4), 171-182.
  79. Jenkins, G.J.S., Chaleshtori, M.H., Song, H., Parry, J.M. Mutation analysis using the restriction site mutation (RSM) assay. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 405(2), 209-220.
  80. Jenkins, G.J.S., Mitchell, I.D.G., Parry, J.M. Enhanced restriction site mutation (RSM) analysis of 1,2-dimethylhydrazine induced mutations, using endogenous p53 intron sequences. Mutagenesis 12(3), 117-123.

Books

  1. Falk, G.W., Jacobson, B.C., Riddell, R.H., Rubenstein, J.H., El-Zimaity, H., Drewes, A.M., Roark, K.S., Sontag, S.J., Schnell, T.G., Leya, J., Chejfec, G., Richter, J.E., Jenkins, G., Goldman, A., Dvorak, K., Nardone, G. Barrett's esophagus: prevalence-incidence and etiology-origins.
  2. Jenkins, G.J.S., Johnson, G.E., Parry, J.M., Doak, S.H. Genotoxic Impurities.
  3. Stamp, D., Jenkins, G. An overview of bile-acid synthesis, chemistry and function.
  4. Jenkins, G., Cronin, J. Bile acids and oesophageal adenocarcinoma (oa).
  5. Jenkins, G.J.S. Molecular Biomethods Handbook.